Search

Your search keyword '"Kwong, Yok‐Lam"' showing total 1,683 results
Start Over Author "Kwong, Yok‐Lam"
1,683 results on '"Kwong, Yok‐Lam"'

3. Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group

Author

Gill, Harinder, Leung, Garret M. K., Ooi, Melissa G. M., Teo, Winnie Z. Y., Wong, Chieh-Lee, Choi, Chul Won, Wong, Gee-Chuan, Lao, Zhentang, Rojnuckarin, Ponlapat, Castillo, Ma. Rosario Irene D., Xiao, Zhijian, Hou, Hsin-An, Kuo, Ming-Chung, Shih, Lee-Yung, Gan, Gin-Gin, Lin, Chien-Chin, Chng, Wee-Joo, and Kwong, Yok-Lam

Published
2023
Full Text
View/download PDF

8. Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial

Author

Zeidan, Amer M, Ando, Kiyoshi, Rauzy, Odile, Turgut, Mehmet, Wang, Ming-Chung, Cairoli, Roberto, Hou, Hsin-An, Kwong, Yok-Lam, Arnan, Montserrat, Meers, Stef, Pullarkat, Vinod, Santini, Valeria, Malek, Kamel, Kiertsman, Flavia, Niolat, Julie, Ramos, Pedro Marques, Menssen, Hans D, Fenaux, Pierre, Miyazaki, Yasushi, and Platzbecker, Uwe

Published
2024
Full Text
View/download PDF

10. Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study

Author

Bachy, Emmanuel, Savage, Kerry J., Huang, Huiqiang, Kwong, Yok-Lam, Gritti, Giuseppe, Zhang, Qingyuan, Liberati, Anna Marina, Cao, Junning, Yang, Haiyan, Hao, Siguo, Hu, Jianda, Zhou, Keshu, Petrini, Mario, Russo, Filomena, Zhang, Huilai, Sang, Wei, Ji, Jie, Ferreri, Andrés José María, Damaj, Gandhi Laurent, Liu, Hui, Zhang, Wei, Ke, Xiaoyan, Ghiggi, Chiara, Huang, Sha, Li, Xiaotong, Yao, Hui, Paik, Jason, Novotny, William, Zhou, Wenxiao, Zhu, Hongjie, and Zinzani, Pier Luigi

Published
2023
Full Text
View/download PDF

15. Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies

Author

Thanarajasingam, Gita, Minasian, Lori M, Bhatnagar, Vishal, Cavalli, Franco, De Claro, R Angelo, Dueck, Amylou C, El-Galaly, Tarec C, Everest, Neil, Geissler, Jan, Gisselbrecht, Christian, Gormley, Nicole, Gribben, John, Horowitz, Mary, Ivy, S Percy, Jacobson, Caron A, Keating, Armand, Kluetz, Paul G, Kwong, Yok Lam, Little, Richard F, Matasar, Matthew J, Mateos, Maria-Victoria, McCullough, Kristen, Miller, Robert S, Mohty, Mohamad, Moreau, Philippe, Morton, Lindsay M, Nagai, Sumimasa, Nair, Abhilasha, Nastoupil, Loretta, Robertson, Kaye, Sidana, Surbhi, Smedby, Karin E, Sonneveld, Pieter, Tzogani, Kyriaki, van Leeuwen, Flora E, Velikova, Galina, Villa, Diego, Wingard, John R, Seymour, John F, and Habermann, Thomas M

Published
2022
Full Text
View/download PDF

17. A proteome‐wide analysis unveils a core Epstein–Barr virus antibody signature of classic Hodgkin lymphoma across ethnically diverse populations.

Author

Sarathkumara, Yomani D., Xian, Rena R., Liu, Zhiwei, Yu, Kelly J., Chan, John K. C., Kwong, Yok‐Lam, Lam, Tai Hing, Liang, Raymond, Chiu, Brian, Xu, Jun, Hu, Wei, Ji, Bu‐Tian, Coghill, Anna E., Kelly, Ashton M., Pfeiffer, Ruth M., Rothman, Nathaniel, Ambinder, Richard F., Hildesheim, Allan, Lan, Qing, and Proietti, Carla

Subjects
VIRAL antibodies, HUMORAL immunity, ANTIBODY formation, HODGKIN'S disease, ONCOGENIC viruses
Abstract

Epstein–Barr virus (EBV) is an oncogenic virus associated with various malignancies, including classical Hodgkin lymphoma (cHL). Despite its known association, the specific role of humoral immune response to EBV remains poorly characterized in cHL. To address this, we conducted a study using a custom protein microarray to measure the antibody responses in cHL patients and matched healthy controls recruited from an East‐Asian hospital‐based case–control study. We identified 16 IgG antibodies significantly elevated in EBV‐positive cHL compared with controls, defining an "East‐Asian antibody signature of EBV‐positive cHL." We evaluated responses against these 16 antibodies in a distinct European population, leveraging data from our previous European cHL case–control study from the UK, Denmark, and Sweden. A subset of antibodies (14/16, 87.5%) from the "East‐Asian antibody signature of EBV‐positive cHL" exhibited significant associations with cHL in the European population. Conversely, we assessed the "European antibody signature of EBV‐positive cHL" identified in our prior study which consisted of 18 EBV antibodies (2 IgA, 16 IgG), in the East‐Asian population. A subset of these antibodies (15/18, 83.3%) maintained significant associations with cHL in the East‐Asian population. This cross‐comparison of antibody signatures underscores the robust generalizability of EBV antibodies across populations. Five anti‐EBV IgG antibodies (LMP‐1, TK, BALF2, BDLF3, and BBLF1), found in both population‐specific antibody signatures, represent a "core signature of EBV‐positive cHL." Our findings suggest that the antibody responses targeting these core EBV proteins reflect a specific EBV gene expression pattern, serving as potential biomarkers for EBV‐positive cHL independent of population‐specific factors. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2

Author

Moffitt, Andrea B, Ondrejka, Sarah L, McKinney, Matthew, Rempel, Rachel E, Goodlad, John R, Teh, Chun Huat, Leppa, Sirpa, Mannisto, Susanna, Kovanen, Panu E, Tse, Eric, Au-Yeung, Rex KH, Kwong, Yok-Lam, Srivastava, Gopesh, Iqbal, Javeed, Yu, Jiayu, Naresh, Kikkeri, Villa, Diego, Gascoyne, Randy D, Said, Jonathan, Czader, Magdalena B, Chadburn, Amy, Richards, Kristy L, Rajagopalan, Deepthi, Davis, Nicholas S, Smith, Eileen C, Palus, Brooke C, Tzeng, Tiffany J, Healy, Jane A, Lugar, Patricia L, Datta, Jyotishka, Love, Cassandra, Levy, Shawn, Dunson, David B, Zhuang, Yuan, Hsi, Eric D, and Dave, Sandeep S

Subjects
Genetics, Cancer, Hematology, Lymphoma, Rare Diseases, Clinical Research, Biotechnology, Digestive Diseases, 2.1 Biological and endogenous factors, Aetiology, Animals, DNA Copy Number Variations, Enteropathy-Associated T-Cell Lymphoma, Female, Gene Expression Profiling, Gene Silencing, Histone-Lysine N-Methyltransferase, Humans, Male, Mice, Knockout, Middle Aged, Mutation, Sequence Analysis, DNA, T-Lymphocytes, Medical and Health Sciences, Immunology
Abstract

Enteropathy-associated T cell lymphoma (EATL) is a lethal, and the most common, neoplastic complication of celiac disease. Here, we defined the genetic landscape of EATL through whole-exome sequencing of 69 EATL tumors. SETD2 was the most frequently silenced gene in EATL (32% of cases). The JAK-STAT pathway was the most frequently mutated pathway, with frequent mutations in STAT5B as well as JAK1, JAK3, STAT3, and SOCS1 We also identified mutations in KRAS, TP53, and TERT Type I EATL and type II EATL (monomorphic epitheliotropic intestinal T cell lymphoma) had highly overlapping genetic alterations indicating shared mechanisms underlying their pathogenesis. We modeled the effects of SETD2 loss in vivo by developing a T cell-specific knockout mouse. These mice manifested an expansion of γδ T cells, indicating novel roles for SETD2 in T cell development and lymphomagenesis. Our data render the most comprehensive genetic portrait yet of this uncommon but lethal disease and may inform future classification schemes.

Published
2017

27. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations

Author

Au, Wing-Yan, Chiu, Brian, Fan, Lei, Li, Zheng, LAM, Tai Hing, Liang, Raymond, Yeh, Su-Peng, Xu, Jun, Ip, Dennis Kai Ming, Li, Gandi, Xu, Gang, Wang, Xiaodong, Bai, Ou, Cai, Qing-Qing, Xia, Yi, Chen, Jie-Rong, Luo, Chun-Ling, Xiong, Xiang-Yu, Zeng, Yanni, Wei, Pan-Pan, Liu, Chu-Jun, Liu, Yu-Xiang, Cao, Yu-Lu, He, Shuai, Liu, Yang, Ha, Jeslin Chian Hung, Khoo, Lay Poh, Kee, Rebecca Xiangpin, Tan, Jing, Liu, Yanhui, Zhang, Fen, Feng, Yanfen, Rao, Huilan, Chng, Wee Joo, Chan, Jason Yong Sheng, Somasundaram, Nagavalli D/O, Tao, Miriam, Ras, Mohamad Farid Bin Harunal, Yeoh, Kheng-Wei, Goh, Yeow Tee, Ong, Shin Yeu, Grigoropoulos, Nicholas Francis, Wong, Esther Kam Yin, Pang, Jane Wan Lu, Lim, Jing Quan, Chia, Burton Kuan Hui, Kim, Seok Jin, Yoon, Sang Eun, Choi, Seungkyu, Kuo, Ching-Yuan, Chen, Tsai-Yun, Su, Yu-Chieh, Huang, Wen-Tsung, Lee, Ming-Yang, Yao, Wenxiu, Ngan, Kai-Cheong, Liu, Herman, Lee, Harold, Yip, Sze-Fai, Liu, Jie, Li, Jianyong, Rabkin, Charles S., Berndt, Sonja, Bassig, Bryan, Hu, Wei, Zhao, Mingfeng, Li, Yuming, Zhai, Qiongli, Shao, Zonghong, Qiu, Lugui, Wang, Jianxiang, Xu, Fu-Ping, Chen, Ling, Hou, Yu, Xu, Shuangnian, Huang, Zhen, Xie, Mingling, Li, Ming, Zhong, Shilong, Zhang, Yan, Gu, Dongqing, Wang, Xin, Foo, Jia Nee, Li, Zhiqiang, Dai, Juncheng, Sun, Liangdan, Wang, Zhenzhen, Liu, Hong, Zhou, Hui, Sun, Yonghu, Koh, Woon-Puay, Heng, Chew-Kiat, Hong, Chew Soo, Ahn, Jeeyun, Park, Kyu Hyung, Tin, Aung, Gu, Jieruo, Xia, Xiaojun, Li, Bo, Yu, Xueqing, Lin, Guo-Wang, Xu, Caigang, Chen, Kexin, Huang, Hui-Qiang, Chen, Jieping, Song, Bao, Chan, John K C, Li, Wenyu, Liu, Weiping, Shih, Lee-Yung, Chuang, Wen-Yu, Kim, Won Seog, Tan, Wen, Peng, Rou-Jun, Laurensia, Yurike, Cheah, Daryl Ming Zhe, Huang, DaChuan, Cheng, Chee Leong, Su, Yi-Jiun, Tan, Soo-Yong, Ng, Siok-Bian, Tang, Tiffany Pooi Ling, Han, Kyudong, Wang, Vivien Ya-Fan, Jia, Wei-Hua, Pei, Zhong, Li, Ya-Jun, Gao, Song, Shi, Yongyong, Hu, Zhibin, Zhang, Furen, Zhang, Ben, Zeng, Yi-Xin, Shen, Hongbing, He, Lin, Ong, Choon Kiat, Lim, Soon Thye, Chanock, Stephen, Kwong, Yok-Lam, Lin, Dongxin, Rothman, Nathaniel, Khor, Chiea Chuen, Lan, Qing, and Bei, Jin-Xin

Published
2020
Full Text
View/download PDF

29. Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial

Author

Zeidan, Amer M, primary, Ando, Kiyoshi, additional, Rauzy, Odile, additional, Turgut, Mehmet, additional, Wang, Ming-Chung, additional, Cairoli, Roberto, additional, Hou, Hsin-An, additional, Kwong, Yok-Lam, additional, Arnan, Montserrat, additional, Meers, Stef, additional, Pullarkat, Vinod, additional, Santini, Valeria, additional, Malek, Kamel, additional, Kiertsman, Flavia, additional, Niolat, Julie, additional, Ramos, Pedro Marques, additional, Menssen, Hans D, additional, Fenaux, Pierre, additional, Miyazaki, Yasushi, additional, and Platzbecker, Uwe, additional

Published
2023
Full Text
View/download PDF

31. Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma

Author

Lim, Jing Quan, Huang, Dachuan, Tang, Tiffany, Tan, Daryl, Laurensia, Yurike, Peng, Rou-Jun, Wong, Esther Kam Yin, Cheah, Daryl Ming Zhe, Chia, Burton Kuan Hui, Iqbal, Jabed, Grigoropoulos, Nicholas Francis, Nairismägi, Maarja-Liisa, Ng, Cedric Chuan Young, Rajasegaran, Vikneswari, Hong, Huangming, Kim, Seok Jin, Cho, Junhun, Tse, Eric, Mow, Benjamin, Cai, Qi-Chun, Poon, Li-Mei, Cai, Qing-qing, Tan, Jing, Chan, Jason Yongsheng, Lim, Johnathan Xiande, Goh, Yeow Tee, Phipps, Colin, Rötzschke, Olaf, Cheng, Chee Leong, Ha, Jeslin Chian Hung, Khoo, Lay Poh, Loh, Yvonne Su Ming, Au-Yeung, Rex, Chan, Thomas Sau-Yan, Kwong, Yok-Lam, Hwang, William, Kim, Won Seog, Bei, Jin-Xin, Lin, Tongyu, Ong, Choon Kiat, and Lim, Soon Thye

Published
2020
Full Text
View/download PDF

33. Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study

Author

Huang, Huiqiang, Zhu, Jun, Yao, Ming, Kim, Tae Min, Yoon, Dok Hyun, Cho, Seok-Goo, Eom, Hyeon Seok, Lim, Soon Thye, Yeh, Su-peng, Song, Yuqin, Kwong, Yok Lam, Kim, Jin Seok, Jin, Jie, Shi, Yuankai, Kim, HyeJin, Qing, Min, Zhou, Tianyuan, Gao, Grace, Dong, Zongqi, Qi, Ming, and Kim, Won Seog

Published
2021
Full Text
View/download PDF

34. Characterization of the humoral immune response to the EBV proteome in extranodal NK/T-cell lymphoma

Author

Liu, Zhiwei, Sarathkumara, Yomani D., Chan, John K. C., Kwong, Yok-Lam, Lam, Tai Hing, Ip, Dennis Kai Ming, Chiu, Brian C.-H., Xu, Jun, Su, Yu-Chieh, Proietti, Carla, Cooper, Martha M., Yu, Kelly J., Bassig, Bryan, Liang, Raymond, Hu, Wei, Ji, Bu-Tian, Coghill, Anna E., Pfeiffer, Ruth M., Hildesheim, Allan, Rothman, Nathaniel, Doolan, Denise L., and Lan, Qing

Published
2021
Full Text
View/download PDF

39. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies

Author

Thanarajasingam, Gita, Minasian, Lori M, Baron, Frederic, Cavalli, Franco, De Claro, R Angelo, Dueck, Amylou C, El-Galaly, Tarec C, Everest, Neil, Geissler, Jan, Gisselbrecht, Christian, Gribben, John, Horowitz, Mary, Ivy, S Percy, Jacobson, Caron A, Keating, Armand, Kluetz, Paul G, Krauss, Aviva, Kwong, Yok Lam, Little, Richard F, Mahon, Francois-Xavier, Matasar, Matthew J, Mateos, María-Victoria, McCullough, Kristen, Miller, Robert S, Mohty, Mohamad, Moreau, Philippe, Morton, Lindsay M, Nagai, Sumimasa, Rule, Simon, Sloan, Jeff, Sonneveld, Pieter, Thompson, Carrie A, Tzogani, Kyriaki, van Leeuwen, Flora E, Velikova, Galina, Villa, Diego, Wingard, John R, Wintrich, Sophie, Seymour, John F, and Habermann, Thomas M

Published
2018
Full Text
View/download PDF

41. S211: EFFICACY AND SAFETY OF ROPEGINTERFERON ALFA-2B FOR PRE-FIBROTIC PRIMARY MYELOFIBROSIS AND DIPSS LOW/INTERMEDIATE-1 RISK MYELOFIBROSIS: UPDATED RESULTS AND GENOMIC CHARACTERISTICS

Author

Gill, Harry, primary, Au, Lester, additional, Tsai, Dorothy, additional, Leung, Man Kit Garret, additional, Yim, Rita, additional, Chin, Lynn, additional, LI, Vivian, additional, Lee, Paul, additional, Sin, Chung Fung Albert, additional, Hou, Hsin-An, additional, Chen, Chih-Cheng, additional, and Kwong, Yok Lam, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results